Author: paroukatos

Norman M Kaplan, Lionel H Opie Hypertension remains the most common risk factor for cardiovascular morbidity and mortality. Its incidence is rising in both ageing and obese populations, but its control remains inadequate worldwide. We address several persisting controversies that may interfere with appropriate management of...

6o Πανελλήνιο συνέδριο - Σύγχρονες απόψεις στην Κλινική Διαχείριση των Παραγόντων Καρδιαγγειακού Κινδύνου 31 Μαΐου- 2 Ιουνίου 2019 Ξενοδοχείο "Ionian Blue" Λευκάδα...

ΑΝΔΡΕΑΣ ΠΙΤΤΑΡΑΣ MD Ο Κιρκάδειος τύπος διακύμανσης της Αρτηριακής πίεσης Κλινικές και θεραπευτικές επιπτώσεις Blood pressure varies widely over 24 hours, and this may contribute to the fact that acute cardiovascular events peak in the morning hours. Reducing morning BP may prevent these occurrences, and so identifying...

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the...

STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP CCB than an RAS inhibitor/thiazide diuretic in hypertensive patients with metabolic syndrome. STAR: rationale Metabolic syndrome associated with increased risk of new-onset diabetes and cardiovascular disease. Antihypertensive therapy may be beneficial in reducing...

TROPHY - hypothesis The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension. TROPHY - objectives Primary: to determine whether treatment with...